About BioStem Technologies Inc. (BSEM)

BioStem Technologies, we’re all about breakthrough anti-aging and regenerative medicine that leverages the body’s innate healing capabilities. Our mission is to discover, develop, acquire, and commercialize effective and profitable anti-aging and regenerative medicine. If it helps reverse, stop, or slow the effects of biological aging (or related acute disease) and if it can be produced, sold or licensed at a good profit, it’s “on strategy” for us, regardless of whether it’s a pharmaceutical, cellular, clinical, nutraceutical, or cosmeceutical therapy. If it’s effective and profitable, we are committed to commercializing it in whatever form and distribution channel is most appropriate. With our broad base of expertise, BioStem Technologies is uniquely positioned to capture a wide range of those revenue and intellectual property opportunities, and at the same time, mitigate much of the “evolving market” risk for our shareholders.

BioStem Technologies Inc. (BSEM) Company Structure



BioStem Technologies Inc. (BSEM) Capital Structure
Total Authorized: 975,000,000
Total Outstanding: 3,476,666
Float: 617,362
Shareholders: 221

BioStem Technologies Inc. Board of Directors

BioStem Technologies Inc. (BSEM) Executive Team

BioStem Technologies Inc. (BSEM) News

BioStem Technologies Inc. (OTC PINK: BSEM) Announces Audit Process and Uplisting Plans to the OTCQX Market